Animas closes $10m purchase of Cygnus:
This article was originally published in Clinica
Executive Summary
West Chester, Pennsylvania insulin infusion pump maker Animas has completed its asset purchase from Cygnus. The $10m cash deal, which was announced in December 2004, brings Animas electrochemical sensor continuous blood glucose monitoring technology, which Cygnus had commercialised as the GlucoWatch Biographer device. This product had a tendency to cause skin irritation. After the breakdown of a distribution deal with Sankyo, Cygnus shareholders agreed to the company's dissolution. Animas intends to replace GlucoWatch's reverse electro-iontophoresis procedure for extracting glucose molecules with micro-needle technology it recently exclusively licensed from Debiotech.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.